Last updated on April 2017

A Study on Eradication Rate of Triple Therapy According to Treatment Period and CYP2C19 Polymorphisms in H.Pylori Patients


Brief description of study

This study compared efficacy and safety of basic triple therapy according to treatment period. This study evaluated Effect of CYP2C19 genetic polymorphisms on the efficacy

Detailed Study Description

This study compared efficacy and safety of basic triple therapy including Noltec(Ilaprazole) 10mg, Clapaxine(Clarithromycin) 500mg and Pamoxin Cap(Amoxicillin) 1000mg BID on the first line eradication treatment of H.pylori according to treatment period. Participants are defined as persons who have endoscopically confirmed on gastric or duodenal ulcer(including scar stage) and gastritis confirmed to be H.pylori positive patients in the UBT test. For 7 days or 10 days Participants treated as basic triple therapy including Noltec(Ilaprazole) 10mg, Clapaxine(Clarithromycin) 500mg and Pamoxin Cap(Amoxicillin) 1000mg BID. After treatment, The healing rate was evaluated in the UBT test at 49±5days from the first day dosing. The investigators would point out the impact of CYP2C19 genotypes on Clarythromycin-based first-line and rescue therapies.

Clinical Study Identifier: NCT03099876

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Dongsoo Lee, MD, PhD

The Catholic Univ. of Korea Daejeon St.Mary Hospital
Daejeon, Korea, Republic of
  Connect »

JaeKyu Sung, MD, PhD

The Chunngnam Univ. General Hospital
Daejeon, Korea, Republic of
  Connect »

Sunghee Jung, MD, PhD

The Eulji Univ. General Hospital
Daejeon, Korea, Republic of
  Connect »

Sunmoon Kim, MD, PhD

The Konyang Univ. General Hospital
Daejeon, Korea, Republic of
  Connect »